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RECENT ADVANCEMENTS IN CANCER IMMUNOTHERAPEUTICS 
SUSIE KIM 
ABSTRACT 
 Cancer affects a wide range of organs and tissues within the body and 
epidemiologically is forecasted to affect almost half of the world’s population. As an 
industry, cancer therapeutics represent a booming field. Standard treatment options, 
however, still heavily rely upon chemotherapeutics developed over fifty years ago. The 
past decade has seen a huge proliferation of different types of cancer drugs. Recently, an 
entirely new class of drugs has been unveiled and holds promising results of preventing 
further relapse incidents. Immunotherapeutics come in many varieties and currently 
several strategies are under intense investigation. Because these drugs harness the body’s 
own immune system to specifically attack tumor cells, these drugs hold an advantage to 
current therapeutic options in that they induce notably less severe side effects, facilitating 
patients’ abilities to maintain quality of life. In addition, these drugs potentially hold the 
promise to cure certain types of cancer, as the body’s memory T cells will prevent relapse 
of the same tumor type. This review will focus on dendritic cell-based therapies, which 
attempt to program these antigen-presenting cell types to prime T cell responses, 
checkpoint blockade drugs that inhibit immunosuppression, and neoadjuvants that aim to 
render the surrounding tumor microenvironment more susceptible for immune attack. In 
addition, some documented and projected downsides to immunotherapeutics will be 
discussed, as well as the need to combine multiple modalities in order to create an 
effective and personalized treatment regimen for cancer patients. 
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1. INTRODUCTION 
 
Cancer represents a heterogeneous group of diseases affecting multiple organs 
and organ systems. A multitude of risk factors predict the likelihood of developing 
various cancers, from inherent genetic predispositions to environmental exposures. The 
World Health Organization estimates that 8.2 million people died worldwide from cancer 
in 2012 (World Health Organization, 2015). Based on 2009-2011 data, approximately 
40.4% of the U.S. population will be diagnosed with cancer during their lifetime, 
according to the National Cancer Institute (National Cancer Institute, 2015). Early 
detection can significantly impact the chances of survival, and for leading causes of 
cancer there are well-established – although not entirely failproof – screening methods. 
For men, prostate cancer can be detected early within routine primary care check-ups 
through blood serum PSA screening; and breast cancer in women can be checked through 
self-administered breast exams and mammogram screenings (World Health Organization, 
2015). 
 Clinically, most cancers are staged based on the TNM classification, with some 
exceptions such as bone marrow cancers. This system utilizes the size of the tumor (T), 
the spread of the tumor to nearby lymph nodes (N), and the metastasis of the tumor to 
more distant organ systems (M). Once this information is gathered, a stage of 0-4 is 
given, which will influence the course of treatment prescribed as well as patient 
prognosis.  
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Table 1: The TNM Staging. Clinical diagnosis of cancer is based upon TNM staging, 
with higher stages correlating to more advanced tumors and statistically decreased 
chances of survival past five years post-diagnosis (National Cancer Institute, 2015). 
 
 
 The early 20th century marks the beginning of cancer therapy. In 1941, Yale 
pharmacologists Louis Goodman and Alfred Gilman created nitrogen-based mustard gas 
as a less volatile alternative in chemical warfare. A year later, a thousand soldiers aboard 
a cargo ship were exposed to a lethal dose of sulfur mustard gas. Autopsy results showed 
significant myelosuppression, as well as lymph node and bone marrow destruction 
(Devita and Chu, 2008). To Goodman and Gilman, these results suggested that controlled 
doses of a safer alternative – namely, nitrogen mustard – represented a novel therapeutic 
route in treating lymphatic tumors. When the pharmacologists transplanted lymphoid 
tumors into mice and treated them with nitrogen mustard, they observed marked tumor 
regressions. These results led to the first administration of nitrogen mustard in a human 
patient with non-Hodgkin’s lymphoma (Chabner and Roberts, 2005). Within a couple 
weeks, the tumor had regressed. Although this remission was brief at best and the tumor 
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regression was incomplete, this finding sparked a flurry of interest in developing new 
methods to combat cancer (Chabner and Roberts, 2005; DeVita and Chu, 2008) 
 Despite their failure to cure cancer, Goodman and Gilman began to pursue the 
molecular mechanisms behind tumor regression-inducing nitrogen mustard. Early in their 
research, they established that neoplastic tissues could be more susceptible to toxins than 
non-neoplastic tissues and that nitrogen mustard seemed to interact with DNA by 
alkylating specific sites on purine bases, which induced apoptosis of the cell (Devita and 
Chu, 2008). These combined results are the basis for many generations of research on 
cancer drugs developed to interact directly with tumor cell DNA. Many classes of drugs, 
including cyclophosphamides and alkylating agents, are still used today (Weir et al., 
2011). 
 A second approach was developed by Sydney Farber at Harvard Medical School 
with the observation that children with megaloblastic anemia required folic acid 
supplementation in their diet; however, when children with this pre-existing condition 
also had acute lymphoblastic leukemia, administration of folic acid drastically stimulated 
the proliferation of their tumor cells (Mukherjee, 2011). Folate analogues, such as 
methotrexate, were thus developed to suppress the function of dihydrofolate reductase, 
required in the synthesis of the DNA base thymidine (Devita and Chu, 2008). Although 
administration of antifolates also resulted in only transient remissions, the idea of 
suppressing tumor cell growth by inhibiting enzymes required for DNA synthesis was 
again established (Mukherjee, 2011). 
! 4!
 By the 1960’s, radiation and surgery were still the prevailing strategies utilized in 
treating cancer. Still, it became increasingly clear that eradicating further instances of 
cancer after remission would require a different approach than even the most radical and 
damaging forms of radiation therapy, as the cure rate with radiation alone remained at a 
low 33% (DeVita and Chu, 2008). In 1974, the idea of adjuvant therapy took hold when 
co-administration of methotrexate with another antifolate, leucovorin, resulted in 
sustained remission for osteosarcoma patients after surgical removal of the tumor. A 
multimodal approach to treating cancers – surgical removal of the tumor, radiation 
ablation of micrometastases, and combination chemotherapy to eliminate any remaining 
malignancies – have since become the therapeutic standard in clinical practice to this day 
(Chabner and Roberts, 2005). 
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Figure 1: Landmark cancer drugs over the past century. Until the 1980’s, the types of 
drugs developed to combat cancer were variants of the first classes of chemotherapeutics, 
which targeted rapidly-proliferating cells, neoplastic and non-neoplastic alike. With the 
development of imatinib in 1996, targeted therapies have begun to emerge (Devita and 
Chu, 2008). 
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 The need to discover new cytotoxic drugs that target rapidly proliferating tumor 
cells has been supplanted by a growing recognition to understand the molecular and 
genetic basis for disease. With the initiation and completion of the Human Genome 
Project, it has become significantly easier to screen for specific mutations in a cohort of 
patients and ascertain the functional significance of such genes. Cancer therapy is 
increasingly moving towards targeted therapy, wherein patients are able to seek unique 
and personalized therapies based on mutations present. 
Searching for mutations shared by patients in the loss of function for tumor 
suppressor genes and gain of function for proto-oncogenes has unearthed an entirely new 
industrial sector in biotechnology, in which mostly small biotechnology firms set out to 
identify mutations and produce drugs that reverse causative mutations. This represents a 
multi-billion dollar industry. In 2005, for instance, the total expenditures worldwide on 
cancer-related products represented nearly $43 billion. This is due in part to the 
monopoly held by newly approved drugs and the increasing variety of drugs from which 
therapeutic options can be chosen (Chabner and Roberts, 2005). 
 One recent landmark event in targeted therapy has been the development of 
imatinib mesylate (Gleevec) by Novartis, a small molecule inhibitor of the constitutively 
active Bcr-Abl tyrosine kinase (Huang et al., 2013). Inhibition of this tyrosine receptor 
prevents uncontrollable phosphorylation of key regulatory proteins in various 
downstream signaling cascade pathways (Huang et al., 2013). Imatinib induces complete 
cytogenetic responses in 76% of chronic myelogenous leukemia by blocking the nuclear 
BCR-ABL tyrosine receptor and promoting apoptosis (Vanneman and Dranoff, 2012). 
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Other applications of the drug are also currently under investigation; for example, studies 
are underway to determine whether imatinib also inhibits the overexpressed HER2/neu 
tyrosine kinase receptor in breast cancer (Vanneman and Dranoff, 2012). Thus, it has 
multiple applications for cancer-causing mutations in tyrosine kinase receptors (Chabner 
et al., 2011). 
 One inherent issue with this drug, as well as subsequently developed tyrosine 
kinase inhibitor drugs, is the tumor cell’s ability to evolve various drug-resistant 
mechanisms, such as developing additional mutations to physically deter the drug from 
binding to target receptors or expressing multi-drug receptors to expel the drug upon 
intracellular entry (Chen and Fu, 2011). The result is that regressions resulting from 
imatinib or other tyrosine kinase inhibitor therapy are commonly followed by relapses, 
the second tumor now insensitive to the previous form of therapy (Vanneman and 
Dranoff, 2012). The invariable acquisition of resistance to tyrosine kinase inhibitors and 
related targeted therapies highlights the pressing need to find a new strategy that offers a 
long-term benefit to sustaining remission. 
 The concept of utilizing the body’s immune system to fight against tumors is not 
new and has been a proposed concept since the beginning of the 20th century (Gajewski, 
2012); however, recent advances in immunology has led to the first of many 
immunotherapeutics becoming FDA approved within the last decade. These therapeutic 
strategies attempt to upregulate the antitumor response by either modulating the tumor 
microenvironment to render the tumor more susceptible to attack or to mobilize immune 
cells to specifically attack tumor cells. Generally, immunotherapy strategies include 
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antibodies, cytokines, vaccines, and adoptive cell therapies. This paper will address the 
therapeutic strategies for dendritic cell-based therapies and checkpoint blockade 
therapies, adjuvant therapies for tumor microenvironment modulation, and practical 
applications of the FDA-approved prototypes of these therapies including economic and 
quality of life parameters. 
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2. DENDRITIC CELL-BASED THERAPIES 
 
Section 2.1: An Introduction to Dendritic Cells 
 
Much interest has been sparked in understanding dendritic cells (DCs) within the 
past forty years upon the realization that DCs can present foreign antigens to naïve T 
cells and initiate potent T cell responses (Banchereau and Steinman, 1998). Dendritic 
cells, so termed due to the many fine spindles of sheets all over the cell body, are a non-
polarized cell type that belong to a class of leukocytes, along with B cells and 
macrophages, called “professional” antigen-presenting cells (APCs) based on their 
expression of both class I and class II MHC molecules, and their ability to present antigen 
to CD4+ T cells. They reside in peripheral tissues easily accessible to foreign antigens, 
such as the skin and the inner lining of the gastrointestinal tract (Banchereau and 
Steinman, 1998). Cancer vaccines targeting DCs can therefore be injected either 
intramuscularly or intradermally within an outpatient setting for efficient takeup. In 
addition, they are motile as a function of their morphology. These features fit the function 
of DCs, which is to capture antigens and present them to T cells (Banchereau and 
Steinman, 1998). DCs will load fragments of the antigen onto their cell surface with 
MHC molecules and travel in their mature form to draining lymph nodes to initiate the 
differentiation of effector T cells with unique functions. Of all professional APCs, DCs 
are considered the most efficient and induce more potent T cell responses than B cells 
and macrophages; thus, they are uniquely capable of priming naive T cells to initiate 
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immune responses (Steinman et al., 2003). 
Historically, clinical interest in DCs has focused on their ability to prime and 
induce CD8+ T cell proliferation, which leads to the generation of cytotoxic T 
lymphocytes (CTLs) and memory CD8+ T cells. This is partially because solid tumors 
often express Human Leukocyte Antigen (HLA) class I and rarely class II molecules, 
making them susceptible for CD8+ CTL attack (Koski et al., 2008).  
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Figure 2: Antigen presentation to DCs. Antigens from outside are taken up into the 
body and detected by APCs such as DCs through various capture mechanisms. 
Subsequent migration of the APC into lymphoid organs is closely followed by the 
maturation of the DC to educate naïve T cell and induce T cell proliferation (Palucka and 
Banchereau, 2013). 
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Section 2.2: Antigen Presentation and T Cell Stimulation 
 
In order to present exogenous antigens, APCs will load fragments of the antigen 
onto MHC Class II molecules if the APC has taken up an exogenous antigen (Melief, 
2008). This can occur either in endocytic compartments by lysosomal proteases, 
cathepsins, or IRAPs (Melief, 2008). For instance, if a virus or bacterial DNA enters the 
cell, the cell’s machinery will synthesize the foreign proteins, which will then be sheared 
into short peptide sequences by the proteasome and bound to class I molecules in the 
endoplasmic reticulum.  
Class I complexes specifically interact with CD8+ effector T cells that require co-
stimulatory molecules on the APC such as CD80 and CD86, as well as cytokines for 
differentiation (Warger, 2006). CTLs are efficient in eliminating cells exhibiting the 
foreign antigen, exerting their cytotoxic effects specifically on cells already containing 
the foreign antigen through releasing granzymes and perforins that puncture holes into 
the cell membrane in order to leak the contents of the cell out into the interstitial space 
(Banchereau et al., 2012). 
Evidence has suggested that memory T cells must first go through an effector 
phase in order to become memory cells (Schluns and Lefrançois, 2003; Opferman, 1999), 
but it is also possible that there are many other undiscovered mechanisms responsible for 
the generation of memory cells. Memory CD8+ T cells survive without extended 
presentation of the foreign antigen; indeed, homeostasis of memory T cells is induced by 
a low level of CTL proliferation (Schluns and Lefrançois, 2003). They proliferate slowly 
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in the absence of the target antigen by homeostatic cytokines secreted by the DCs with 
which they are seen to cluster in lymphoid organs (Ku, 2000; Geginat, 2003). Lying 
dormant within the body, they only become activated when the antigen is presented for a 
second time, at which time the immune system mounts a faster and robust response. The 
potentiation and maintenance of memory CD8+ T cells increases the appeal for 
immunotherapy because treatment for the cancer and prevention of future relapses can 
both be administered within a few doses.  
DCs also extend their effects to the innate immune system by interacting with the 
tumor microenvironment and recruiting NK cells. This is a bidirectional interaction, with 
DCs secreting CXCR3 ligands to promote NK function (Martín-Fontecha et al., 2004). In 
turn, NKs not only release the necessary cytokines to activate the adaptive immune 
system and induce helper T cell (Th) responses (Martín-Fontecha et al., 2004) but also 
stimulate DC maturation and eliminate those DC subtypes that promote tolerance 
(Bonaccorsi et al., 2013). 
It is now established, however, that targeting CD8+ cells with antigens complexed 
to MHC Class I molecules will trigger only weak and short-lived responses (Pouyanfard 
et al., 2012). Thus, cancer vaccines targeting CD4+ T cell priming are now increasingly 
under research and development. These cell types have been shown to clear tumors 
without the help of CD8+ T cells and are perhaps more efficient in eliminating tumors by 
themselves in vivo than CD8+ cells alone by recruiting NK cells to reject tumors that are 
resistant to CD8-mediated tumor rejection (Perez-Diez et al., 2007). CD4+ T cells 
differentiate into helper T cell type 1 (Th1), which is the primary mechanism utilized in 
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vaccinations due to their secretion of IFN-γ, implicated in tumor rejection models for 
several cancers including breast cancer (Nanni et al., 2004). In addition, Th1 cells aid in 
sensitizing CD8+ T cells to detect tumor antigen-bound MHC class I molecules as well 
as to upregulate CTL differentiation (Czerniecki et al., 2007). CD4+ T cells also 
differentiate into follicular helper cells (Tfh), which contribute to the differentiation of B 
cells into plasma cells that produce antibodies and memory B cells (Crotty, 2011). DCs 
can also have a direct impact on the proliferation and differentiation of B cells through 
the release of specific cytokines (Caminschi and Shortman, 2012).  
On the other hand, CD4+ can also differentiate into two cell types that may have 
pro-tumorigenic effects. Type 2 Th (Th2) cells in murine models have been reported to 
secrete IL-4 and IL-13, both of which play central roles in immunosuppression (Aspord 
et al., 2007). Yet earlier reports also give conflicting evidence that Th2 cells may have 
antitumor effects that are admittedly less effective than Th1-mediated antitumor activity 
(Nishimura et al., 1999). In addition, certain subsets of DCs will induce the generation of 
CD4+ FoxP3+ regulatory T cells (Tregs) (Steinman et al., 2003), which act to inhibit T 
responses by either directly acting upon Th cells or on DCs. (Tarbell et al., 2007). Theses 
observations that DCs can prime different classes of T cells to perform in opposing ways 
add to the complexity involved in designing DC-based therapies to promote antitumor T 
cell function. 
DCs supporting tolerance in normal physiology are crucial to moderate 
responses to harmless antigens or to self-antigens, as can be seen when 
dysregulated in allergy responses. On the other hand, in complex tumor 
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microenvironments DCs can also act to suppress immune function by eliminating 
T cells or inhibiting T cell priming (Steinman et al., 2003). Most tolerogenic DCs 
are, interestingly, immature DCs (iDCs). To rephrase, iDCs are by default 
tolerogenic unless activated by foreign antigens to mature into stimulatory DCs 
(sDCs) and exhibit markedly different features, such as decreased levels of 
intracellular MHC stock, enhanced antigen presenting and co-stimulatory 
capabilities (Maldonado and von Andrian, 2010). Some sDCs may eventually 
become exhausted (exDCs) and lose their immunostimulatory capabilities. 
Tolerogenic DCs, a specialized subtype of DC, encompass both natural 
tolerogenic DCs that exist at steady-state for anti-inflammatory function and 
induced tolerogenic DCs that exist in pathological states (Maldonado and von 
Andrian, 2010). Many mechanisms fall within tolerogenic DCs’ capabilities, 
including both the activation of existing Tregs and promotion of Treg 
differentiation, as well as deletion and functional inhibition of effector T cells 
(Maldonado and von Andrian, 2010). 
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Figure 3: A schematic for the development of tolerogenic and immunogenic DCs. 
Most immature DCs and mature tolerogenic DCs promote tolerogenicity, while immature 
DCs stimulated by foreign antigens can become activated and promote immunogenicity. 
(Maldonado and von Andrian, 2010).  
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Section 2.3: Immunosuppresion and Tolerance 
 
 Induced tolerogenic DCs arise either after therapeutic intervention or in 
pathologies. In the case of cancer, tumors can inhibit DC maturation and release 
cytokines to maintain tissue-resident DCs and tissue-infiltrating DCs in their immature 
state, decreasing their ability to recruit T cells and increasing Treg activity. This 
represents a potential way in which tumors evade immune patrol.  
Tumors not only develop mechanisms to escape immune surveillance but also 
rewire the immune system to promote tumor tolerance. There is evidence that DCs 
migrate to the tumor site at early stages of breast cancer and immature DCs infiltrate the 
tumor in vivo while mature DCs with clusters of CD4+ T cells exist around the tumor 
periphery (Bell et al., 1999). This suggests that the tumor itself may release cytokines to 
sustain immature DCs to circumvent immune activation. To substantiate this, evidence 
now suggests that breast cancer tumors release IL-13 and phosphorylated STAT6 
(Aspord et al., 2007), the latter of which is considered a downstream marker of IL-13 
signaling. IL-13 is the primary cytokine that represses CTL-mediated tumor 
immunosurveillance and plays a central role in promoting tumor growth through and 
suppressing immunosurveillance. In cancer patients, DC dysfunction within the tumor 
microenvironment is significantly influenced by tumor-derived factors. The list of 
includes VEGF, M-CSF, IL-6, low pH from the glycolytic pathways tumor cells utilize to 
metabolize in tissue hypoxic situations, IL-10, and COX2, among many others 
(Gabrilovich et al., 2012). 
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The name “vaccine” in cancer immunotherapeutics is perhaps misleading because 
these drugs are not meant to be prophylactic; rather, they are designed to target pre-
existing and proliferating tumors while improving the body’s guard against potential 
relapse. DNA vaccines are similar in drug delivery design to gene therapy. Anticancer 
vaccines have had to overcome major theoretical hurdles, as it has only recently become 
apparent that many cancers, such as breast cancer, are immunogenic and therefore able to 
potentiate an immune response. Detractors to this theory historically had pointed out that 
cancers stem from “self” tissues and would not be distinguishable by the immune system, 
which targets only foreign antigens. Renewed interest in anticancer vaccines arose in the 
1990’s with the discovery that neoplastic cells could present immunogenic tumor-
associated antigens on their cell surface that could be targeted by the immune system 
(Matzinger, 1994). 
 
Section 2.4: Currently available DC-based therapeutic options and limitations 
 
DC-based vaccination therapy was first initiated in animal models of cancer and 
applied to human patients in 1996. In May 2010, the FDA approved the usage of 
Sipuleucel-T (trade name Provenge) by Dendreon Corporation, for the treatment of 
metastatic prostate cancer. Sipuleucel-T is now undergoing several clinical trials, in 
varying phases of development, for different cancer types and in conjunction with 
neoadjuvants as well. The first FDA-approved drug for DC-based therapy, this drug 
represents significant benefits not only in prolonging life expectancy but also in reducing 
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healthcare costs and increasing patient compliance by reducing the number of hospital 
visits required for treatment. Yet current understanding of DCs and their co-dependence 
on the tumor microenvironment, as well as knowledge of tumor-specific antigens, are 
limited (Onji and Fazle Akbar, 2008) and thus create a major obstacle in the development 
of more DC-based therapies in the application of various types of cancer. In clinical 
trials, many potential therapeutics fail to achieve clinical efficacy, partly due to limited 
knowledge of serum markers specific to the cancer in question (Onji and Fazle Akbar, 
2008). This perhaps explains why many anti-cancer drugs now in clinical trials target 
such cancers as prostate cancer, with its universally accepted serum marker PSA, and 
melanoma, well-characterized in its multitude of specific antigens (Onji and Fazle Akbar, 
2008).   
At least 26 distinct DC populations exist based on surface markers and 
immunological functions in vivo. These subsets can be classified by one key 
differentiation step from a common myeloid progenitor: plasmacytoid DCs (pDCs) that 
exist in nonlymphoid tissues and classic DCs (cDCs) that reside in lymphoid organs – 
spleen, thymus, and lymph nodes – and in the blood as migratory cDCs (Miller et al., 
2012). Physiological pDCs differ from cDCs in their low class II expression, rendering 
them more likely to effect CD8+ T cells, and altogether poor ability to stimulate T cells. 
They also have a predilection for stimulating Th2 cells, which cause unwanted effects 
(Datta, Jashodeep et al., 2014). In spite of these characterizations, pDCs are attractive 
candidates for DC-based therapies due to their ability to respond to viral infections 
through upregulated expression of TLR 7 and 9 and secretion of IFN-α/β (Liu, 2005), 
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hereby having an increased ability to induce T cell proliferation and secrete 
antitumorigenic cytokines than migratory cDCs (Evelkabler and Chen, 2006). In addition, 
pDCs cultured ex vivo are seen to sustain function long after injection in murine models 
and become as active as in vivo pDCs following interaction with viruses (O’Keeffe et al., 
2002), which eliminates therapeutic restrictions in clinical administration. Currently, 
however, cDCs are more often used due to the incompleteness of our understanding of 
pDC function. The successful development of DC-based therapies therefore relies on a 
more thorough evaluation of different DC subtypes. 
Because of their innate propensity to mobilize the immune system, DC-based 
therapies are currently under intense research, both in academic and pharmaceutical 
sectors. Two strategies, ex vivo DC engineering and in vivo DC targeting, are most 
widely adopted. The ex vivo strategy has been researched for a slightly longer period than 
in vivo targeting and therefore has more candidate drugs currently undergoing clinical 
trials.  
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Section 2.5: Ex vivo Targeting 
 
The general strategy behind ex vivo DC targeting is as follows: 
 
1. Blood samples are taken from a patient and either monocytes or hematopoietic 
progenitors are collected; 
2. Progenitor cells are cultured with a cocktail of cytokines to generate DCs and 
expanded ex vivo; 
3. The DCs are loaded with antigens, either through transfecting the DCs with 
tumor-derived RNA, transfection of adenoviral vectors containing target gene 
sequences, or by adsorptive pinocytosis of protein antigens (Onji and Fazle 
Akbar, 2008). These are then administered back to the patient. 
4.  
This strategy has three likely benefits. Firstly, the DCs cultured are derived from 
the patient and therefore likely to have far less side effects than conventional 
chemotherapy and radiation treatments. In support of this aspect, the majority of clinical 
trials have indicated that DC-based therapies preserve quality of life for immunized 
patients (Leonhartsberger et al., 2012) and antigen-specific immunity is induced even in 
advanced metastatic cancers (Anguille et al., 2014). Secondly, the DCs are pre-
engineered to bypass unwanted immunosuppressive effects. Thirdly, the DCs would 
cause differentiation of T cells in an antigen-specific manner so that the therapy would 
target the tumor and impart less damage to non-cancerous tissues than conventional 
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therapies. 
 
Figure 4: Strategies for TAA presentation to DCs for targeted therapy.  For in vivo 
DC loading, a vaccine is injected and presented to physiological DCs to exert their 
effects. For ex vivo targeting, DC precursors are taken from the patient’s body and 
cultured to engineer TAA-specific sDCs that can then be injected back into the patient 
(Vanneman and Dranoff, 2012). 
 
There are drawbacks to DC-based therapy that highlight inherent issues in the 
field of personalized medicine. Given the incomplete knowledge of all tumor-associated 
antigens, this strategy is highly dependent on the discovery of new tumor-specific 
markers. Moreover, to tailor the treatment to a patient’s unique tumor, DNA microarrays 
or RNA-sequencing must be performed, increasing the cost of healthcare per course of 
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treatment for the patient. Sipuleucel-T, administered in three doses for a full course of 
treatment, cost $93,000 in 2011 (Anassi and Ndefo, 2011), although this cost would 
likely decrease after patent expirations and the development and FDA approval of 
competing DC-based therapies. By comparison, the most commonly-prescribed 
chemotherapeutic drug –docetaxel – costs $40,000 for a typical course of treatment, or 10 
cycles of admininistration (Anassi and Ndefo, 2011). Sipuleucel-T is also covered by 
Medicare (Anassi et al., 2011) and next-generation DC-based therapies may also be 
covered, increasing healthcare cost burden in the United States. Although lifespan is 
extended and quality of life maintained during treatment is objectively much better with 
Sipuleucel-T treatment than newly-approved chemotherapeutics, much controversy 
remains as to whether the therapy, as the prototype to future DC-based therapies, is cost-
effective on many levels (Gong and Hay, 2014).   
The way in which the antigen is introduced to the DC remains a controversial 
topic. The most common approach is to use either recombinant proteins or tumor lysate 
containing the tumor-associated protein for uptake into the cell. DC vaccinations against 
TAAs in humans and mice result in T cell expansion and proliferation; however, many 
failed clinical trials report that these T cells still fail to significantly stymie tumor 
progression, suggesting that the effects function only at the cellular level and that the host 
immune system still manages to sustain self-tolerance to these tumor-associated antigens 
(Evelkabler and Chen, 2006). 
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Table 2: Advantages and disadvantages of injecting vaccines directly into the tumor 
(Van der Jeught et al., 2015). 
 
 
One strategy to maximize tumor targeting is to utilize whole tumor lysates derived 
from the patient in order to generate a collection of DCs targeting multiple TAAs (Chen 
et al., 2010). This method offers the obvious benefit of presenting multiple TAAs to 
induce CTL response and eliminate the need to discover TAAs specific to the patient, 
making it more efficient to personalize the vaccine to the patient. In addition, in both 
animal models and clinical trials, the usage of whole tumor lysate has been shown to have 
low toxicity and be highly effective in a variety of cancers (Schnurr et al., 2001). 
However, in order to generate the whole tumor lysates, sufficient amounts of tumor cells 
must be collected from the patient. In addition, a considerable amount of “self” proteins 
can be included in the tumor lysate, generating unwanted tolerogenic DCs that generate 
adverse immunosuppressive responses.  
Another strategy is to inject “empty” DCs directly into the tumor that the DCs can 
capture TAAs and travel within lymphatic vessels to present the TAAs to T cells. When 
injected with the appropriate cytokines, the DC could be induced to mature and prime T 
cell response, thus bypassing both the creation of immature DCs and induced tolerogenic 
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DCs that would suppress immune function. In early clinical trials, however, this strategy 
also resulted in nonsignificant outcomes because the empty DCs injected were found to 
colocalize within the tumor instead of migrating to lymphoid organs. In vitro analysis 
also revealed that retention of DCs within the tumor was partially mediated by tumor 
production of chemokines – specifically, IL-8 – that attracted DCs and blocked DCs 
outside the tumor microenvironment from migrating (Feijoó et al., 2005). Further pursuit 
of this strategy is dependent on discovering appropriate adjuvants that modulate the 
tumor microenvironment and race against the tumor’s ability to evolve to allow the DC to 
capture TAAs and migrate to lymphoid organs housing naïve T cells. 
Evaluating the clinical efficacy of DC-based therapy also is variable depending on 
the dosing regimen and methods of administration. These two parameters must be 
optimized for each patient, which may partially account for failures in clinical trials 
several target therapeutics have experienced. For instance, because DCs have migratory 
abilities, some DC-based therapies, such as Sipuleucel-T, are administered via 
intravenous administration to the lymph nodes (Plosker, 2011). There is, however, 
ongoing debate concerning the optimal route of administration, with some evidence 
pointing to intradermal or subcutaneous injection or even direct injection into the lymph 
node and tumor itself (Onji and Fazle Akbar, 2008).  
  
! 26!
Section 2.6: In vivo Targeting 
 
In vivo DC targeting is a newer therapeutic strategy and attempts to deliver 
antibody-tumor-associated antigen complexes to DC surface molecules, thus eliminating 
the need to engineer TAA-targeted DCs outside the body. The general strategy is as 
follows: 
 
1. A target TAA sequence – DNA, RNA, or protein – is injected either intradermally 
or intramuscularly 
2. Certain types of tissue-resident DCs, such as Langerhans cells in the epidermis, 
pick up the foreign antigen and complex them onto MHC molecules; 
3. The patient is monitored over a period of time to ascertain the successful uptake 
of antigen and presence of targeted DCs. 
 
In vivo targeting provides a more efficient and cost-effective strategy than ex vivo 
targeting. Currently, DNA- and RNA-based therapies are most researched due to the 
ability to target known receptors on the DC surface. In their immature form, DCs are 
extremely efficient in capturing foreign antigens through receptors such as toll-like 
receptors (TLRs) and C-type lectin receptors (CLRs). In order to target these receptors, 
adenoviral or lentiviral vectors are typically used to deliver the TAA (Datta et al., 2014). 
At least 11 varieties of TLRs have been discovered to recognize conserved 
homologous regions of microbial or viral structures called pathogen-associated molecular 
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patterns (PAMPs) that help discern sequences not found in the host and are therefore 
foreign matter. For instance, TLR9 is associated with CpGs, which are cytosine- and 
guanine-rich regions of DNA that are rarely found in vertebrate DNA and more 
commonly found in bacterial DNA. There are currently several clinical trials that target 
TLR9 alone. A study by Shirota et al showed that myeloid-derived suppressor cells, 
which are a type of immune cell that give rise to such APCs as DCs and macrophages, 
showed markedly reduced suppressive function and increased differentiation into 
macrophages showing tumoricidal activity (Shirota et al., 2012). Another group has 
already completed Phase I clinical trials targeting TLR9 to stimulate CD8+ CTL activity, 
with 5 of 11 patients showing tumor regression after administration (Molenkamp et al., 
2008). Other TLR receptors are currently under investigation and at varying stages of 
clinical development. 
CLRs, on the other hand, represent a class of receptors recognizing specific 
carbohydrate domains of foreign antigens. Under normal physiological circumstances, 
CLRs such as mannose receptors recognize carbohydrates present on the cell walls of 
certain pathogens and rapidly process peptide epitopes onto either MHC Class I and II 
molecules (Engering et al., 1997). The most commonly targeted receptor for vaccines 
currently under development is DEC-205, an endocytic receptor with multi-lectin 
domains that is expressed abundantly on DCs in lymphoid organs and generates antigen-
MHC Class II complexes for antigen presentation (Bonifaz et al., 2002). Several studies 
have indicated the capacity for DEC-205-targeted antigens to initiate huge proliferation 
of T cells with the co-administration of agonistic CD40 antibodies to induce the 
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maturation of these DCs (Hsu et al., 1990). In addition, the half-life of DEC-205-targeted 
antigens is prolonged, which has a significant impact on dosage requirements in clinical 
settings (Chakrabarty et al., 1990).  
One particular vaccine strategy under development is to target the mannose 
receptor MUC-1. MUC-1 is a tumor oncoprotein expressed on a number of organs and is 
especially upregulated in breast cancer (Apostolopoulos et al., 2006). Phase III 
immunotherapy and fifteen-year follow-up studies were conducted using a fusion protein 
combining MUC-1 with an oxidized mannan protein to stimulate DC maturation and 
subsequent T cell activation specific to MUC-1. Of note, the fifteen-year follow-up 
revealed 2/16 incidences of late relapse, as opposed to 9/15 relapses in the control group, 
revealing a long-term benefit to utilizing this therapy. Even more impressive, 
immunological side effects experienced during were relatively minimal and no long-term 
adverse side effects have been reported up to 16.5 years later, including autoimmunity to 
self-antigens (Apostolopoulos et al., 2006). Other clinical studies for various DC vaccines 
have laid to rest concerns that DC-based therapies would lead to long-term development 
of autoimmune diseases. Indeed, the accepted notion now is that DC-based vaccinations 
maintain quality of life for the patient and are safe (Katano et al., 2005, Chung et al., 
2013, Vik-Mo et al., 2013). 
An inherent challenge in targeting DCs in vivo is to prod the DC to mature and 
induce immunogenic responses following administration of the foreign antigen. Specific 
adjuvants must be co-administered in order to trigger the appropriate response. One 
strategy currently under much scrutiny even beyond cancer vaccine research is to 
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combine co-stimulatory molecules with TLR agonists to induce DC maturation. In one of 
the first studies into this approach, a combination of TLR7 and CD40 agonists was 
administered and was found to increase CD8+ tumor-infiltrating T cell activity by 10-20 
times from baseline and targeting different TLRs with CD40 resulted in similar 
upregulation of T cell activity (Ahonen et al., 2004). A second strategy, to co-administer 
TLR agonists with co-inhibitory molecule antagonists such as anti-CTLA-4 (discussed 
later) into the tumor resulted in the depletion of tumor-resident Tregs, resulting in the 
eradication of the targeted tumor and distant metastases (Marabelle et al., 2013). These 
preclinical results offer the supporting evidence of sustained antitumor activity. 
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3. CHECKPOINT BLOCKADE 
 
Section 3.1: The Co-stimulation Model 
 
Figure 5: Mapping the interaction of co-stimulatory and co-inhibitory molecules on 
APCs, T cells, and the tumor microenvironment. A multitude of receptors and ligands 
control T cell responses and several of these are currently under investigation as potential 
therapeutic targets for immunotherapy (Ott et al., 2013). 
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 The immune system comprises a delicate homeostatic balance between activation 
of immune responses against signals deemed harmful – often foreign pathogens – and 
suppression of immune responses against signals deemed harmless. Imbalances towards 
overstimulation of the immune system are manifest in such states as allergies, in which 
the immune system is over-stimulated against relatively harmless antigens from the 
environment, and multiple sclerosis, in which the immune system harmfully attacks self-
derived peripheral nervous tissue. In contrast, a suppressed immune state can lead to the 
inability to fight infections. Cancer cells not only escape immune attack but also exploit 
the immune system and suppress the microenvironment in which tumor cells are encased 
to better aid proliferation, as will be discussed in subsequent sections. 
 The way in which the immune system regulates responses against harmful and 
harmless antigens can be explained through the idea of co-stimulation, or that two signals 
are required to either activate or suppress immune responses. The first signal requires 
lymphocytic recognition of specific antigens through the interaction of the T cell receptor 
with the antigen-MHC complex on an antigen-presenting cell (APC). Following 
recognition, a second signal – termed “co-stimulatory” signals – is required to start or 
terminate a T cell-mediated response (Sharpe and Freeman, 2002). The model is 
substantiated through evidence that, without co-stimulatory signals, T cells exhibit 
suppressed function. Furthermore, the interactions of T cells with co-stimulatory signals 
also seem to vary depending on such parameters as antigen concentration, adding another 
level of complexity to immune design. 
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 Further research into co-stimulatory and co-inhibitory molecules has unearthed 
several molecules that regulate T cell activity. Of these, Cytotoxic T Lymphocyte-
associated Antigen-4 (CTLA-4) and Programmed Cell Death Protein-1 (PD-1) inhibitors 
have been recently FDA approved and represent a new class of drugs available in clinics 
to treat metastatic cancers and prevent further incidence. Other checkpoint inhibitors, 
such as LAG-3 and TIM-3, are also in late stages of clinical development and show 
promising data from clinical trials. 
Checkpoint inhibitors such as CTLA-4 and PD-1 blockade upregulate the activity 
of T cells by interrupting immune suppression. These blockade drugs are monoclonal 
antibodies that bind specifically to a single cell receptor on T cells and have a long 
plasma life, which lowers the dosing frequency (Chabner et al., 2011). Although these 
drugs do not directly target tumor cells, increasing the body’s adaptive immunity allows 
for increased immunosurveillance. Clinical data available for inhibitors of these two 
targets show that these drugs offer the potential for incidence-free survival. 
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Figure 6: A simplified diagram illustrating the two-signal model. APCs present 
antigens to the T cell, which bind to the T cell receptor. A second signal will then bind to 
CTLA-4 and PD-1, which checkpoint blockade drugs will target to stop 
immunosuppression (Postow and Momtaz, 2014). 
 
Section 3.2: CTLA-4 
 
 CTLA-4 is a co-inhibitory molecule expressed on several types of T cells, 
including constitutive expression on Tregs and effector T cells, as well as memory CD4+ 
T cells (Peggs et al., 2009a). It competes with CD28, a stimulatory receptor constitutively 
expressed on the surface of T cells, for binding to both CD80 and CD86 with 2- to 3-fold 
higher affinity than CD28 (Linsley et al., 1994). CD80 and CD86 are both expressed on 
most APCs, although CD80 is inducibly expressed after activation and CD86 is 
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constitutively expressed at low levels. While CD28 is a co-stimulatory molecule, CTLA-
4 suppresses T cell activation and expansion even with the presence of CD28 due to its 
higher affinity. Upon antigen presentation, the naïve or memory T cell is activated and 
CTLA-4 expression is upregulated, further potentiating the inhibitory signal.  
 The mechanism of action for CTLA-4 has not yet been fully elucidated. Anti-
CTLA-4 therapy requires CTLA-4 targeting on both Treg and effector T cells (van Elsas 
et al., 1999). Anti-CTLA-4 treatment seems to be partly dependent on the activity of 
CTLs and some evidence points to CD4+ T cell-mediated activation of CTLs as the moda 
operandi of CTLA-4 blockade (Peggs et al., 2009b), although recent reports suggest that 
Treg suppression is actually the main moda operandi of CTLA-4 blockade (Vogel et al., 
2015). Antibodies to CTLA-4 can also inhibit or eradicate Tregs within the tumor (Selby 
et al., 2013). These mechanisms, however, also may account for unwanted autoimmune-
like side effects patients report with CTLA-4 blockade therapy. 
It has further been demonstrated that patient responsiveness to CTLA-4 blockade 
had a positive correlation to the mutational load in the TAA-MHC Class I complex. In 
other words, increased density and type of mutations is associated with long-term clinical 
benefit derived from anti-CTLA-4 drugs, possibly because higher mutational load would 
increase the chances that the neoepitope is recognized and targeted as a “non-self” 
antigen by circulating T cells (Snyder et al., 2014). Indeed, a separate study found that 
30-40% of melanoma patients seem to have “inflamed” tumors with CD8+ T cells that 
spontaneously differentiated to target tumor antigens. These patients seem to respond 
better to anti-CTLA-4 therapy (Gajewski, 2012). In addition, responsiveness to anti-
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CTLA-4 therapy in melanoma patients seems to correlate to a specific tetrapeptide 
sequence from all TAA-MHC Class I complexes that are otherwise unique to the patient, 
although a few patients without this sequence still benefited from therapy. In contrast, 
patients who did not exhibit meaningful clinical benefit did not have this tetrapeptide 
sequence (Snyder et al., 2014). These results reveal a predisposition to CTLA-4 for some 
patients that can be measured and, thus, predicted. 
Thus far, one anti-CTLA-4 drug has been FDA-approved for clinical use in the 
United States. Ipilimumab, by Medarex and Bristol-Myers Squibb, was approved in 2011 
for clinical use by the U.S. F.D.A. It is a fully humanized IgG1 monoclonal antibody for 
the treatment of metastatic melanoma (Wolchok et al., 2013). As mentioned before, 
melanoma has well-characterized biomarkers that allow for consistent and reliable results 
from clinical trials. Several clinical trials for ipilimumab in treating other cancers such as 
lung cancer (Bristol-Myers Squibb; U.S. National Institutes of Health) and metastatic 
hormone-refractory prostate cancer (Mayo Clinic; U.S. National Institutes of Health) are 
currently under way. One round of treatment consists of 4 doses at 3 mg/mL every three 
weeks (Bristol-Myers Squibb, 2013).  
 Impressively, ipilimumab treatment has resulted in one of the longest periods of 
relapse-free survival for patients. In Phase III clinical trials, ipilimumab was shown to 
improve overall survival of patients with metastatic melanoma by 28%, compared to 
conventional chemotherapy. Further monitoring up to four years after initial treatment 
was conducted for 177 patients who had undergone Phase II ipilimumab treatment. In 
contrast to the 15% survival rate for stage IV melanoma with conventional therapies, 
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patients who received their first does of ipilimumab four years ago reported a markedly 
improved survival rate of 37.7% - 49.5% (Wolchok et al., 2013). Notably, many of these 
patients who had been treated with ipilimumab had been diagnosed with even poorer 
prognoses due to such factors as elevated serum LDH levels. Follow-up of patients from 
phase III trials indicated that the average time needed for complete eradication of the 
tumor was 30 months after the start of treatment, suggesting that the Phase II clinical trial 
data for ipilimumab monotherapy perhaps did not illustrate the long-term effectiveness of 
the drug. Indeed, one patient required treatment six years before achievement of a 
complete response. 
 In contrast to other types of drugs, ipilimumab has also not shown to induce drug 
resistance. In a study by Robert et al, patients who initially benefit from ipilimumab 
treatment and relapse with a second tumor were successfully re-treated with ipilimumab, 
with durable tumor responses lasting several years by the end of the study. This suggests 
that the initial tumor presents different TAAs that are recognized by the T cells upon the 
first round of treatment than subsequently arising tumors, so new tumors can successfully 
evade an established set of T cells recognizing a certain group of TAAs. Re-
administration of ipilimumab therefore stimulates T cells to recognize the new group of 
TAAs, with similar toxicities as experienced during initial rounds of treatment (Robert et 
al., 2013). This represents a highly attractive feature of ipilimumab and other 
immunotherapeutics. 
 Ipilimumab elicits inflammation in a variety of tissues, as reported by patients. 
The most commonly affected tissues are the skin, bowel, liver, pituitary, and endocrine 
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glands. These side effects can partially be mollified by the interruption or discontinuation 
of the drug or with co-administration of immunosuppressive drugs such as prednisone, a 
corticosteroid commonly administered with chemotherapy (Wolchok et al., 2013). Due to 
these most common toxicities, in clinical settings patients with pre-existing autoimmune 
diseases such as multiple sclerosis or lupus are generally not considered for CTLA-4 
blockade therapy (Peggs et al., 2008). 
 Patients can also respond at different time points, with some patients experiencing 
tumor progression before response is noted (Wolchok, 2012). As clinical studies for 
CTLA-4 blockade target mostly metastatic cancer types, the failure of clinical trials may 
imply that the data collected may need to be measured differently in order to illustrate the 
delayed onset of therapeutic efficacy, not the ineffectiveness of the drug (Callahan and 
Wolchok, 2013). 
Immune response is not wholly mediated by CD80/86 – CD28/CTLA4 
interaction. Despite the existence of multiple co-inhibitory pathways, some patients still 
respond positively and durably to CTLA-4 blockade, implying that to these patients 
CTLA-4 may be the primary molecule in which pre-existing, spontaneously-arising, 
TAA-targeting CD4+ and CD8+ T cells are inhibited. 
 
Section 3.3: PD-1 
 
 Other co-inhibitory molecules exist and these pathways are seen to be 
upregulated after CTLA4 inhibition. Yet another important co-inhibitory molecule is PD-
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1, which is inducibly expressed on a wide variety of immune cells, including CD4+ and 
CD8+ T cells, B cells, monocytes, some DC subsets, and NK cells following activation 
(Francisco et al., 2010). PD-1 expression on T cells – most notably, memory T cells – can 
be induced by a number of cytokines such as IL-2, IL-7, IL-15, and IL-21, all of which 
have profound effects on the tumor microenvironment (Kinter et al., 2008). There is 
evidence that expression of PD-1 on tumor-infiltrating lymphocytes (TILs) is associated 
with poorer prognoses for multiple cancer types, including melanoma (Hino et al., 2010) 
and hepatocellular carcinoma (Gao et al., 2009). PD-1 therefore is an important 
biomarker in tumor progression and responsiveness to anti-PD-1 therapy.  
PD-1 and CTLA-4 have distinct spatiotemporal activities. Unlike CTLA-4, which 
acts largely in the lymph nodes, PD-1 acts in peripheral tissues including the tumor 
microenvironment (Ott et al., 2013). CTLA-4 also affects early T cell activation, while 
PD-1 acts upon pre-activated effector T cells (Ott et al., 2013). As its name implies, PD-1 
induces apoptosis of effector T cells and has been shown to cause T cell exhaustion when 
expressed long-term at high levels (Penaloza-MacMaster et al., 2014). On a subcellular 
level, PD-1 interaction with its ligands halts the cell in its G1 phase by increasing the 
expression of G1 phase inhibitor p15 and suppressing SKP2 transcription through PI3K-
Akt and MEK-ERK signaling inhibition (Patsoukis et al., 2012). 
Its ligands, PD-L1 and PD-L2, are differentially expressed on cell types, with PD-
L1 largely expressed on hematopoietic and epithelial cells and PD-L2 expressed mostly 
on APCs. Of the two, PD-1/PD-L1 interaction is thought to mainly mediate PD-1 
blockade in cancer. PD-L2, on the other hand, is implicated in the suppression of 
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autoimmunity; thus, blocking PD-1 may create adverse over-stimulated immune 
response. This may provide an explanation for side effects reported for PD-1 blockade 
drugs, such as autoimmune pneumonitis and nephritis (Kim and Eder, 2014). 
The PD-1/PD-L1 pathway is an especially attractive target for cancer because it is 
constitutively overexpressed in many different tumor types, as well as expressed on cells 
within the surrounding microenvironment (Dong et al., 2002). Thus, it is implicated in 
stimulating tumor progression for several types of cancers. PD-L1 is directly targeted by 
HIF-1α, a characteristic product of tumor hypoxic cells, and upregulated in solid tumors 
(Noman et al., 2014). PD-L1 on APCs can bind CD80 on T cells, indicating a way 
CTLA-4 blockade can be circumvented through upregulation of PD-L1 activity to 
suppress T cell activation and cytokine activation (Butte et al., 2007). PD-L1 blockade 
therefore is also of therapeutic interest and three candidate drugs are currently undergoing 
clinical trials. As other cytokines and co-stimulatory molecules may very well circumvent 
PD-1 blockade alone, it may be of therapeutic importance to utilize a multitherapy 
approach in blocking the PD-1/PD-L1 pathway. 
Two anti-PD-1 drugs are now available on the market. Pembrolizumab, from 
Schering Plough and Merck, was approved in September 2014 and is intended for use in 
metastatic melanoma. Nivolumab, from Medarex and Bristol-Myers-Squibb, was 
approved soon after pembrolizumab in December 2014 and is also intended for use in 
metastatic melanoma no longer responsive to other drugs. Like CTLA-4 blockade, PD-1 
inhibition is typically accompanied by adverse side effects related to autoimmunity, as 
PD-1 under normal circumstances is essential for tolerance. 44% of all patients 
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experienced side effects with potential immune-related causes with nivolumab, although 
all these events were reported to be reversible and noticeably lessened when combined 
with glucocorticoids (Topalian et al., 2012). 79% of patients on pembrolizumab therapy 
reported adverse side effects, although generally the toxicity level was lower than with 
ipilimumab treatment (Robert et al., 2014). Still, these side effects are much more 
tolerable than those experienced with classical therapies. 
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Table 3: Comparison of common anti-cancer agents and toxicity profiles. Of note, 
chemotherapy also has documented immunogenic adverse side effects, like checkpoint 
blockade drugs (Callahan and Wolchok, 2013). 
 
 
Pembrolizumab underwent the largest-ever Phase I clinical trial for patients with 
metastatic melanoma to test toxicity profiles and antitumor effects. Smaller tumor sizes 
correlated with a higher chance of tumor regression by the end of the study, and 38% of 
all patients exhibited significant tumor regression with the treatment (Robert et al., 2014). 
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Phase I clinical trials for nivolumab showed that 28% of patients experienced tumor 
regression, with 13 of 18 patients receiving treatment for more than a year experiencing 
durable responses lasting more than a year post-treatment initiation (Hamid et al., 2013). 
Blocking PD-L1 instead of PD-1 resulted in a slightly lower percentage of patients 
experiencing tumor regression, but also resulted in fewer adverse side effects reported 
(Merelli et al., 2014). Yet antitumor activity with both drugs occurs much more 
frequently with overexpressed PD-L1 expression and in time-limited clinical studies the 
benefit of PD-1 blockade seems only pronounced for a small cohort of patients with 
elevated PD-L1 expression. This highlights a need to develop other checkpoint blockade 
drugs to make available for a wider population of patients, which is currently being 
addressed with research on other checkpoint molecules such as LAG-3 and TIM-3.  
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Figure 7: Durable responses are noted with CTLA-4 blockade and PD-1/PD-L1 
blockade. Combinatorial strategies are hypothesized to increase survival (Ott et al., 
2013). 
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4. MANIPULATION OF THE TUMOR MICROENVIRONMENT 
 
A multitude of therapeutic strategies aim to modulate the tumor 
microenvironment, not only as standalone monotherapies but also as adjuvants for both 
DC-based therapies and checkpoint inhibitor drugs. Traditional chemotherapy has been 
historically viewed as immunosuppressive because these drugs target rapidly dividing 
cells, both neoplastic and non-neoplastic. Damage to healthy cells is therefore a potent 
side effect commonly associated with chemotherapy. Although tumor cells are 
preferentially targeted, leukocytes and bone marrow precursors are also one of the most 
rapidly dividing healthy cells (Weir et al., 2011), which leads to widespread assumption 
that chemotherapy is immunosuppressive. 
Recently, however, chemotherapeutics as an adjuvant to immunotherapy have 
been proposed to condition the tumor cells and render them more susceptible to immune 
attack. Biweekly administration of a low dose of cyclophosphamides in mice for over a 
month results in depleted Treg stores, with higher doses also affecting B and T cell 
expansion (Ghiringhelli et al., 2007). However, there is also evidence that long-term 
administration of low doses of cyclophosphamides also promotes the accumulation of 
myeloid-derived suppressor cells that promote immunosuppression (Ding et al., 2014). 
Another chemotherapeutic, 5-Fluorouracil, has been reported to selectively induce 
myeloid-derived suppressor cell apoptosis within the tumor microenvironment, with 
long-lasting results (Ugel et al., 2012). Additionally, 5-Fluorouracil combined with 
cyclophosphamides showed increased tumor-infiltrating CD8+ T cells, suggesting that at 
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low doses the cytotoxicity of these drugs was largely limited to immunosuppressive cell 
types (Ding et al., 2014). These preliminary findings not only suggest traditional 
chemotherapy as neoadjuvants for immunotherapy but also offer an alternative 
mechanism for how chemotherapeutics in the past have induced tumor regression. 
However, even at low doses chemotherapy has well-documented unwanted 
toxicity, such as organ damage.  As research on cyclophosphamides has shown, 
chemotherapeutics may have dual immunosuppressive and immunostimulatory properties 
that may result in decreasing therapeutic effectiveness of immunotherapy. Cytokine 
therapy has a distinct advantage over chemotherapeutics because this type of therapy 
specifically targets the tumor microenvironment and minimizes damage to other organs. 
The presence of various cytokines within the tumor microenvironment that act to 
repress immune function is not only a descriptive phenomenon but also a potential target 
for neoadjuvants administered with DC-based therapies to optimize vaccination 
strategies. CTLs display a dependence on IL-12 in order to have an effect on breast 
cancer and melanoma cells and within TNM staging patients with higher IL-12 levels in 
general respond better even to conventional therapy than patients with lower IL-12 levels 
(Xu et al., 2003). Moreover, dendritic cells releasing IL-12 can drive Th1-polarized 
immunity to lead to better prognoses in melanoma (Carreno et al., 2013). In an early 
clinical study, DCs were injected into the tumor with an adenovirus containing the IL-12 
gene and administered to patients in a series of three doses. For a vast majority of these 
patients, the adenoviral component was enough to upregulate T cell activity against IL-
12. Although adverse immune side effects were reported – from immunosuppressive 
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events such as lymphopenia to overstimulatory immune events such as fevers – still, 
some patients showed increased NK and CD8+ T cell activity within the tumor 
(Mazzolini et al., 2005). 
Additional fields of research also target intratumoral delivery of IL-2, TNF-α, and 
type I IFNs, all of which in tumor microenvironments are cytokines that promote the 
proliferation of Tregs and effector T cell death (Van der Jeught et al., 2015). 
Combinatorial IL-2 administration and PD-L1 blockade in preclinical studies have shown 
markedly expanded CD8+ T cell responses in chronic inflammation models, suggesting a 
reversal of T cell exhaustion (West et al., 2013). IL-10 and PD-1 blockade seem to 
restore both CD4+ and CD8+ responses more than monotherapy of either drug alone 
(Sun et al., 2015). These reports demonstrate a need to manipulate the tumor 
microenvironment and tailor therapeutic strategies for patients so that tumors cannot 
evade immunotherapeutic targeting.  
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5. DISCUSSION 
 
As immunotherapy becomes more common in oncology, the price of therapy, and 
the willingness of patients and insurers to pay, will become increasingly problematic. 
Every year, the amount spent on cancer healthcare increases. The most recent American 
Cancer Society report cites $88.7 billion dollars spent on the total direct medical costs 
pertaining to cancer in 2011 (National Cancer Institute), approximately $9.8 billion of 
that directly stemming from the cost of prescription drugs. As more competing therapies 
are approved by the FDA and as patent swear out, generic drugs will allow the price of 
each round of treatment to decrease; however, current understanding of cancer therapy 
assumes the necessity to take a multimodal combinatorial approach. Thus, the financial 
costs associated with treating cancer are necessarily high. 
 Yet emerging immunotherapies offer multiple major benefits that not only 
alleviate the economic burden cancer healthcare currently represents but also increase 
patients’ willingness to pay for these expensive therapies. Firstly, immunotherapies hold 
the potential for a cure for cancer; that is, the incidence of relapse after tumor regression 
is far less than with other currently available therapeutic modalities. Thus far, no drug 
resistance has been reported for immunotherapies, so in the case of subsequent relapses 
immunotherapeutic options can still be considered. Secondly, the number of rounds of 
drug administration is significantly less with immunotherapy, which increases patient 
compliance. 50% of all cancer healthcare costs are directly attributable to hospital visits 
(National Cancer Institute) and patients undergoing grueling chemotherapy sessions often 
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experience drastic upheavals in lifestyle and relationship dynamics between the patient 
and family. Profound psychological changes occur during treatment, often irreversible 
even after tumor regression has been achieved. Finally, patients on immunotherapies 
report far less severe side effects, thus allowing for a significantly heightened ability to 
maintain quality of life pre-diagnosis. For difficult-to-treat cancers such as brain cancer, 
immunotherapeutics offer an edge over traditional chemotherapy because minimal 
damage would be inflicted upon surrounding tissues. Therefore, immunotherapies offer a 
non-invasive, markedly safer approach to eradicate residual malignancies post-operation. 
It must be noted, however, that immunotherapy is not an option for all cancers or 
all patients. Patients with pre-existing autoimmune diseases may not be able to tolerate 
the adverse effects of immunotherapy, which could exacerbate their existing 
autoimmunity. This represents a small but significant portion of the population that may 
need to weigh the overall benefits of immunotherapy against their pre-existing 
autoinflammatory conditions. Patients with advanced cancers, for instance, may want to 
risk autoimmune responses to immunotherapy if the alternative is death. 
Also, unlike conventional chemotherapy, there is often a signficant delay from the 
initiation of immunotherapy to the beginning of clinical response. In clinical trials, this 
has often resulted in reputed failures due to the inability of the patient to show significant 
tumor regressions within the specified time window. In addition, the vast majority of 
immunotherapeutic drugs have undergone clinical trials in patients with advanced 
cancers, so many drugs may not have proved efficacious in time. The need for 
immunotherapeutics to be combined with cancer drugs such as monoclonal antibodies 
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and chemotherapy, which have almost immediate effects (Ott et al., 2013), remains to be 
fully addressed and established as a standard clinical procedure. 
Also, immunotherapeutics work best when the cancer in question is immunogenic 
in nature. Tumors can be stratified based on the level of tumor-host immune interaction 
(Lechner et al., 2013). Certain types of cancers such as melanoma and colorectal cancer 
are immunogenic in nature and are therefore more likely to respond to immunotherapy 
(Blankenstein et al., 2012). Some breast cancer lines in vitro have also been identified as 
highly immunogenic and therefore attractive targets for immunotherapy (Lechner et al., 
2013). On the other hand, lung cancer and renal cell carcinoma are considered to be 
poorly immunogenic and therefore more responsive to other forms of therapy 
(Blankenstein et al., 2012). Within subsets of these different cancers, there exists a 
spectrum of immunogenicity that can predict a patient’s overall ability to respond to 
immunotherapy. This complicates the current paradigm of cancer treatment, wherein 
patients are treated with a cocktail of drugs given their cancer type.  
The emergence of immunotherapeutics, in conjunction with the evolution in 
personalized treatment of cancer, has increased this awareness that cancers should not be 
grouped based on the tissue in which the cancer originates. Recently, researchers have 
begun to group cancers based on known biomarkers. This allows for the possibility of 
one cancer drug to treat several different tumor types. Given this information, it is 
unsurprising that many cancer drugs that are currently FDA approved for one type of 
cancer, such as imatinib mesylate for certain types of leukemia, are also currently 
undergoing clinical trials for other cancer types in what is termed a “basket trial” (Menis 
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et al., 2014). Previously, clinical trials for developing drugs targeted one cancer type; 
however, in basket trials one drug can be tested for several types of cancer based on the 
similarities presented in molecular and immune profiling of the patient (Reddig and 
Janne, 2015). As personalized medicine has become the standard of care in cancer 
treatment, the mounting number of therapeutic options in cancer treatment should not be 
limited to a specific cancer type and should instead be available for patients based on 
how they may respond to combination therapy.  
Immunotherapy is not without its limitations and there are certainly patients who 
will not benefit from this type of treatment; however, it is a breakthrough development of 
yet another class of cancer drugs that can prolong a patient’s life and allow for a higher 
quality of life during treatment than conventional chemotherapy offers. Because the field 
is new, many hurdles lie ahead. Optimization of antigen presentation to dendritic cells, 
both in vivo and ex vivo, remains a major challenge in designing an effective cancer 
vaccine. The mechanisms for CTLA-4 blockade are still not fully elucidated and there is 
ongoing debate on whether PD-1 or PD-L1 blockade would be more effective. There 
exists a pressing need to develop adjuvants to weaken the tumor microenvironment’s 
defense mechanisms would allow immunotherapeutic drugs to have more potent effects. 
Even if immunotherapeutic drugs succeed in clinical trials, long-term effects and 
potential side effects have yet to be established. Many questions remain unanswered and 
uncovering the answers to these questions will shape the direction of ultimately 
developing cures for cancer. 
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